Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C N Johnson

Showing results (81-90 of 85) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 85 results.
Journal of Medicinal Chemistry|May 5, 2000
Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): A potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the ratG Stemp, T Ashmeade, C L Branch, et al.
Trials|June 6, 2022
Regulating clinical trials in a resource-limited setting during the Ebola public health emergency in Sierra LeoneOnome T Abiri, Abdulai J Bah, Michael Lahai, et al.
Developments in Biologicals|March 29, 2006
Adaptation of the WHO guideline for residual DNA in parenteral vaccines produced on continuous cell lines to a limit for oral vaccinesJ A Lebron, P J Troilol, S Pacchione, et al.
Science Translational Medicine|July 31, 2020
Scientific considerations for global drug developmentJennifer L Wilson, Kit Wun Kathy Cheung, Lawrence Lin, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 17, 2000
Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-AC Reavill, S G Taylor, M D Wood, et al.
Pageof 9

Showing results (81-90 of 85) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 85 results.
Journal of Medicinal Chemistry|May 5, 2000
Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): A potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the ratG Stemp, T Ashmeade, C L Branch, et al.
Trials|June 6, 2022
Regulating clinical trials in a resource-limited setting during the Ebola public health emergency in Sierra LeoneOnome T Abiri, Abdulai J Bah, Michael Lahai, et al.
Developments in Biologicals|March 29, 2006
Adaptation of the WHO guideline for residual DNA in parenteral vaccines produced on continuous cell lines to a limit for oral vaccinesJ A Lebron, P J Troilol, S Pacchione, et al.
Science Translational Medicine|July 31, 2020
Scientific considerations for global drug developmentJennifer L Wilson, Kit Wun Kathy Cheung, Lawrence Lin, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 17, 2000
Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-AC Reavill, S G Taylor, M D Wood, et al.
Pageof 9